Equities research analysts expect Tyme Technologies Inc (NASDAQ:TYME) to post earnings of ($0.08) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Tyme Technologies’ earnings. Tyme Technologies reported earnings of ($0.04) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 100%. The business is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Tyme Technologies will report full-year earnings of ($0.23) per share for the current financial year. For the next financial year, analysts forecast that the firm will report earnings of ($0.39) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Tyme Technologies.

A number of research analysts have recently weighed in on TYME shares. Zacks Investment Research downgraded Tyme Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, February 15th. BidaskClub raised Tyme Technologies from a “strong sell” rating to a “sell” rating in a research note on Tuesday, February 27th. Finally, ValuEngine raised Tyme Technologies from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $8.25.

Shares of Tyme Technologies traded up $0.21, reaching $3.59, during trading hours on Monday, MarketBeat.com reports. The company had a trading volume of 4,982 shares, compared to its average volume of 282,527. The company has a market cap of $300.40 million, a P/E ratio of -19.39 and a beta of 0.48. Tyme Technologies has a 1-year low of $2.01 and a 1-year high of $9.50.

Institutional investors have recently modified their holdings of the stock. Monashee Investment Management LLC acquired a new stake in Tyme Technologies during the 4th quarter worth $128,000. Wells Fargo & Company MN raised its stake in Tyme Technologies by 923.9% during the 4th quarter. Wells Fargo & Company MN now owns 29,180 shares of the company’s stock worth $186,000 after buying an additional 26,330 shares during the period. BlueCrest Capital Management Ltd acquired a new stake in Tyme Technologies during the 4th quarter worth $247,000. Family Management Corp raised its stake in Tyme Technologies by 27.3% during the 1st quarter. Family Management Corp now owns 140,000 shares of the company’s stock worth $312,000 after buying an additional 30,000 shares during the period. Finally, Millennium Management LLC raised its stake in Tyme Technologies by 314.1% during the 4th quarter. Millennium Management LLC now owns 238,125 shares of the company’s stock worth $1,519,000 after buying an additional 180,620 shares during the period. 9.26% of the stock is currently owned by institutional investors and hedge funds.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company has a co-development agreement with the University of California San Francisco to evaluate SM-88 therapy in prostate cancer.

Get a free copy of the Zacks research report on Tyme Technologies (TYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.